Want to see BNBX full AI Analyst Report?
Top Page
BNB Plus
(OTC:BNBX)
Select Model
Select Model
Rating:41Neutral
Price Target:
$0.14
▲(6.15% Upside)
Action:Upgraded
Date:07/30/26
The score is primarily held down by weak financial performance (extreme losses and heavy cash burn) and very poor technical positioning (price far below major moving averages). Negative corporate developments (Nasdaq delisting/OTCQB move and restructuring-related changes) add risk, while the low-debt balance sheet and financing steps provide only limited offset given the scale of losses.
Positive Factors
Low Leverage
Minimal debt reduces financial risk and limits interest-related pressure on cash flow. This balance-sheet flexibility could help BNB Plus preserve resources, pursue strategic initiatives, or withstand periods of weak operating performance without immediate leverage constraints.
Negative Factors
Severe Profitability Weakness
Extremely negative operating and net margins show that the current revenue base is not covering the company’s cost structure. Margin deterioration despite the revenue rebound suggests that growth has not yet translated into earnings power, leaving profitability recovery as a major durable challenge.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Leverage
Minimal debt reduces financial risk and limits interest-related pressure on cash flow. This balance-sheet flexibility could help BNB Plus preserve resources, pursue strategic initiatives, or withstand periods of weak operating performance without immediate leverage constraints.
Read all positive factors
BNB Plus (BNBX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$896.17K
Dividend YieldN/A
Average Volume (3M)36.84K
Price to Earnings (P/E)―
Beta (1Y)1.52
Revenue Growth-27.39%
EPS Growth99.29%
CountryUS
Employees26
SectorFinancial
Sector Strength70
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding6,197,223
10 Day Avg. Volume29,097
30 Day Avg. Volume36,840
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.87
Price to Sales (P/S)0.94
P/FCF Ratio-0.16
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
BNB Plus Business Overview & Revenue Model
Company Description
BNB Plus Corp., established in 1983 and based in Stony Brook, NY, is a biotechnology firm dedicated to pioneering and commercializing technologies for the synthesis and identification of both deoxyribonucleic acid (DNA) and ribonucleic acid (RNA)....
BNB Plus Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
22
Negative
| Breakdown | TTM | Sep 2025 | Sep 2024 | Sep 2023 | Sep 2022 | Sep 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.09M | 2.14M | 3.43M | 13.37M | 18.17M | 9.03M |
| Gross Profit | 910.30K | 838.91K | 1.02M | 5.53M | 5.05M | 4.93M |
| EBITDA | -34.70M | -15.26M | -13.33M | -9.59M | -12.68M | -11.68M |
| Net Income | -34.48M | -15.16M | -6.99M | -9.95M | -8.38M | -16.03M |
Balance Sheet | ||||||
| Total Assets | 13.63M | 4.44M | 12.79M | 13.65M | 22.27M | 14.42M |
| Cash, Cash Equivalents and Short-Term Investments | 949.09K | 1.67M | 6.43M | 7.15M | 15.22M | 6.55M |
| Total Debt | 0.00 | 193.25K | 739.16K | 1.24M | 0.00 | 0.00 |
| Total Liabilities | 1.50M | 2.50M | 3.82M | 8.78M | 9.36M | 3.30M |
| Stockholders Equity | 12.51M | 2.30M | 9.14M | 4.95M | 12.91M | 11.11M |
Cash Flow | ||||||
| Free Cash Flow | -13.80M | -12.83M | -14.12M | -6.30M | -9.47M | -15.94M |
| Operating Cash Flow | -13.79M | -12.52M | -13.71M | -6.22M | -8.98M | -13.39M |
| Investing Cash Flow | -2.96M | -292.12K | -407.90K | -1.10M | -489.55K | -2.55M |
| Financing Cash Flow | 9.96M | 8.05M | 13.40M | 0.00 | 18.13M | 14.70M |
BNB Plus Technical Analysis
Negative
0.13
Price Trends
0.18
Negative
0.33
Negative
0.89
Negative
Market Momentum
>-0.01
Negative
45.02
Neutral
39.55
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BNBX, the sentiment is Negative. The current price of 0.13 is below the 20-day moving average (MA) of 0.14, below the 50-day MA of 0.18, and below the 200-day MA of 0.89, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 45.02 is Neutral, neither overbought nor oversold. The STOCH value of 39.55 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BNBX.
BNB Plus Risk Analysis
BNB Plus disclosed 41 risk factors in its most recent earnings report. BNB Plus reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
BNB Plus Peers Comparison
UnderperformOutperform
Sector (68)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | $18.00B | 11.42 | 9.92% | 3.81% | 9.73% | 1.22% | |
50 Neutral | $9.07M | -0.96 | -224.80% | ― | ― | 98.17% | |
48 Neutral | $6.75M | -0.24 | -170.36% | ― | 38.09% | 54.22% | |
42 Neutral | $3.88M | -0.03 | -524.37% | ― | -92.11% | 86.78% | |
41 Neutral | $896.17K | >-0.01 | -337.10% | ― | -27.39% | 99.29% |
* Financial Sector Average
BNBX
BNB Plus
0.14
-2.18
-93.79%
NDRA
ENDRA Life Sciences
6.05
1.93
46.84%
INBS
Intelligent Bio Solutions
2.23
-14.22
-86.44%
ISPC
iSpecimen
1.54
-28.34
-94.85%
BGLC
BioNexus Gene Lab Corp
1.45
-3.51
-70.77%
BNB Plus Corporate Events
Business Operations and StrategyExecutive/Board ChangesPrivate Placements and Financing
BNB Plus Reshapes Board With New Investor-Linked Directors
Neutral
Sep 3, 2026
On September 2, 2026, BNB Plus Corp. announced that directors Robert B. Catell, Joseph D. Ceccoli and Dr. Yacov Shamash resigned from the board effective September 3, 2026, with the company stating the departures were not due to disagreements over...
Business Operations and StrategyExecutive/Board ChangesLegal ProceedingsPrivate Placements and FinancingRegulatory Filings and Compliance
BNB Plus Restructures Agreements and Leadership with Cypress
Negative
Jul 29, 2026
On July 23, 2026, BNB Plus and its Cypress-affiliated partners entered into a Settlement Agreement that terminated prior strategic digital asset management, advisory and consulting contracts dating from 2025, in exchange for $1 million in cash ove...
Business Operations and StrategyDelistings and Listing ChangesPrivate Placements and FinancingRegulatory Filings and Compliance
BNB Plus Faces Nasdaq Delisting, Moves to OTCQB
Negative
Jul 13, 2026
On July 10, 2026, BNB Plus Corp. received a delisting determination from a Nasdaq Hearings Panel after the company failed to regain compliance with the $1.00 minimum bid price requirement for continued listing on the Nasdaq Capital Market. Followi...
Business Operations and StrategyPrivate Placements and FinancingRegulatory Filings and Compliance
BNB Plus Amends Registration Rights Agreement Timeline
Neutral
Jul 2, 2026
On June 29, 2026, BNB Plus entered into an amendment, effective June 23, 2026, to its May 26, 2026 Registration Rights Agreement with purchasers holding at least 50.1% of its registrable securities. The amendment extends the filing date for regist...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.